Management of Lower Risk Non-del(5q) MDS

Myelodysplastic syndromes (MDS) are prognostically stratified into lower risk (LR MDS) and higher risk ones, according to the International prognostic scoring systems (both IPSS and IPSS-R)(1,2). IPSS-R prognostic evaluation is based on depth f cytopenias but mainly on cytogenetic abnormalities and the risk is defined as the overall survival and propensity to develop acute leukemia. The great majority of MDS patients belong to lower risk categories, but within such broad definition there are different forms of MDS with quite divergent outcomes.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research